PSC
PSTX

Piper Sandler & Co’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Piper Sandler & Co’s Portfolio PSTX Stock Details PSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-8,298
Closed -$74K – 28
2020
Q3 		$74K Buy
+8,298
New +$94.4K 0.06% 22

Other funds holding PSTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Piper Sandler & Co's PSTX Position: Q4 2020 in Review

Piper Sandler & Co sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q4 2020, closing a stake of 8,298 shares — an estimated $74K sold.

Piper Sandler & Co first reported a position in PSTX in Q3 2020 and held it in 1 quarter. The position peaked at $74K in Q3 2020. 56 funds tracked by Wall St. Rank hold PSTX as of Q4 2020.

  • Piper Sandler & Co reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Piper Sandler & Co sold 8,298 Poseida Therapeutics, Inc. Common Stock shares in Q4 2020, an estimated $74K.
  • Piper Sandler & Co first reported a position in Poseida Therapeutics, Inc. Common Stock in Q3 2020 and held it in 1 quarter.
  • Piper Sandler & Co's Poseida Therapeutics, Inc. Common Stock position peaked at $74K in Q3 2020.
  • 56 funds tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q4 2020.

Based on Piper Sandler & Co's 13F filing for Q4 2020, filed 11 Feb 2021.